LIVEWIRE ERGOGENICS INC. Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2015-09-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2015-09-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2015-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2015-09-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2015-09-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Operating income ÷ reported interest expense. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 67.98K USD | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -656.67K USD | Operating Income (Loss) |
| Interest expense · reported / estimated | -44.01K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2015-09-30 | (m) | $67.98K | (m) | $-656.67K | $-44.01K | (m) | (m) | (m) | Reported |
| 2015-06-30 | (m) | $85.09K | (m) | $-850.65K | $-39.01K | (m) | (m) | (m) | Reported |
| 2015-03-31 | (m) | $189.84K | (m) | $-922.80K | $-42.29K | (m) | (m) | (m) | Reported |
| 2014-12-31 | (m) | $238.96K | $1.75M | $-2.89M | $-653.92K | (m) | 732.84% | (m) | Reported |
| 2014-09-30 | (m) | $237.35K | (m) | $-2.70M | $-673.17K | (m) | (m) | (m) | Reported |
| 2014-06-30 | (m) | $272.69K | (m) | $-2.52M | $-686.87K | (m) | (m) | (m) | Reported |
| 2014-03-31 | (m) | $191.41K | (m) | $-2.70M | $-677.51K | (m) | (m) | (m) | Reported |
| 2013-12-31 | (m) | $146.17K | (m) | $-888.31K | $-59.20K | (m) | (m) | (m) | Reported |
| 2013-09-30 | (m) | $125.07K | (m) | $-1.50M | $-53.53K | (m) | (m) | (m) | Reported |
| 2013-06-30 | (m) | $94.17K | (m) | $-1.57M | $-33.63K | (m) | (m) | (m) | Reported |
| 2013-03-31 | (m) | $121.69K | (m) | $-1.66M | $-26.25K | (m) | (m) | (m) | Reported |
| 2012-12-31 | (m) | $148.03K | (m) | $-1.67M | $-21.02K | (m) | (m) | (m) | Reported |
| 2012-09-30 | (m) | $135.89K | (m) | $-742.39K | $3.38K | (m) | (m) | -219.38× | Reported |
| 2012-06-30 | (m) | $141.81K | (m) | (m) | $2.00K | (m) | (m) | (m) | Reported |
| 2012-03-31 | (m) | $423.91K | (m) | (m) | $2.46K | (m) | (m) | (m) | Reported |
| 2011-12-31 | (m) | $402.34K | (m) | $-390.56K | $2.38K | (m) | (m) | -164.03× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.